Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||ATM R3008H|
|Gene Variant Detail|
|Relevant Treatment Approaches||Olaparib|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ATM R1882* ATM R3008H||pancreatic cancer||predicted - sensitive||Berzosertib + Irinotecan||Case Reports/Case Series||Actionable||In a Phase I trial, the combination of Berzosertib (VX-970) and Camptosar (irinotecan) was tolerated in patients with advanced solid tumors, and resulted in a partial response that was ongoing at 11 months in a pancreatic cancer patient harboring ATM R3008H and germline ATM R1882* (J Clin Oncol 40, 2022 (suppl 16; abstr 3012); NCT02595931).||detail...|